PATENT CLAIM ANALYSIS

Application Number: 15971692
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "014200"]

Abstract:
This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1′ residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.

Claim (Index 11):
A modified serpin according to  claim 10  wherein the wild-type serpin is selected from the group consisting of \u03b1 1 -antichymotrypsin (SERPINA3), C1-esterase inhibitor, \u03b1 2 -antiplasmin (SERPINF2) antithrombin (ATIII) (SERPINC1), heparin cofactor II (HCII) (SERPIND1), protein C inhibitor (PCI) (SERPINA5) or \u03b1 1 -antitrypsin (\u03b1 1 AT) (SERPINA1), Kallistatin (SERPINA4), Plasminogen activator inhibitor (SERPINE1), Protease nexin 1 (SERPINE2) and Protein Z-dependent protease inhibitor (SERPINA10).

Metadata:
- Claim Count in Document: 50.0
- Percentile: 93.0
- Lexical Diversity: 1.22222
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15103420', '11825627', '15034385', '12676203', '12179951']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7126153510624886
- 35 USC 102 Novelty (BERT): 0.5973407541530281
- Combined Prediction Score: 0.7010878913715426
- Mean Citation Score: 310.5061740000001
- Max Citation Score: 645.6493
- Similarity Product: 401.4225986013056

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test